Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam versus best available therapy for ceftazidime-resistant Gram-negative infections
2012-000726-21Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2012
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ceftazidime + avibactam in complicated urinary tract infection (cUTI), Intra-abdominal infection (IAI) and Gram-negative bacterial infection (2 arms), sponsored by AstraZeneca. Primary endpoint: Clinical cure at test of cure in mMITT population. Started Jun 2012; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
complicated urinary tract infection (cUTI)Intra-abdominal infection (IAI)Gram-negative bacterial infection
Beyond the preview
Go deeper on 2012-000726-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000726-21.